NCT00581126View on ClinicalTrials.gov

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

July 31, 2004

Conditions
Hemophilia B
Interventions
DRUG

Recombinant Factor IX Coagulation

Benefix IV each 12 hours for 2 a 5 days

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00581126 - Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B | Biotech Hunter | Biotech Hunter